Table 2.
MSH6 and PMS2 carriers with colonic neoplasia identified
| Colonoscopy before age 50 | Total (N = 113) |
MSH6 (N = 76) |
PMS2 (N = 37) |
P (MSH6 vs. PMS2) |
|---|---|---|---|---|
| Any neoplastic lesion identified before 50 (including advanced lesions, non-advanced lesions, CRC) | 46 (41%) | 32 (42%) | 14 (38%) | 0.69 |
| Any advanced adenoma/advanced serrated lesion identified before 50 | 7 (6%) | 5 (7%) | 2 (5%) | 0.99 |
| Any CRC identified before 50 | 4 (4%) | 3 (4%) | 1 (3%) | 0.99 |
| Colonoscopy before age 30 |
Total (N = 20) |
MSH6 (N = 16) |
PMS2 (N = 4) |
P (MSH6 vs. PMS2) |
| Any neoplastic lesion identified before age 30 (including advanced lesions, non-advanced lesions, CRC) | 9 (45%) | 7 (44%) | 2 (50%) | 1.0 |
| Any advanced adenoma/advanced serrated lesion identified before age 30 | 1 (5%) | 1 (6%) | 0 | 0.99 |
| Any CRC identified before age 30 | 0 | 0 | 0 | - |
| Colonoscopy between ages 30–39 |
Total (N = 46) |
MSH6 (N = 26) |
PMS2 (N = 20) |
P (MSH6 vs. PMS2) |
| Any neoplastic lesion identified between ages 30–39 (including advanced lesions, non-advanced lesions, CRC) | 16 (35%) | 9 (35%) | 7 (35%) | 1.0 |
| Any advanced adenoma/advanced serrated lesion identified between ages 30–39 | 3 (7%) | 1 (4%) | 2 (10%) | 0.57 |
| Any CRC identified between ages 30–39 | 3 (7%) | 2 (8%) | 1 (5%) | 0.99 |
| Colonoscopy between ages 40–49 |
Total (N = 59) |
MSH6 (N = 43) |
PMS2 (N = 16) |
P (MSH6 vs. PMS2) |
| Any neoplastic lesion identified between ages 40–49 (including advanced lesions, non-advanced lesions, CRC) | 28 (47%) | 21 (49%) | 7 (44%) | 0.78 |
| Any advanced adenoma/advanced serrated lesion identified between ages 40–49 | 4 (7%) | 3 (7%) | 1 (6%) | 0.99 |
| Any CRC identified between ages 40–49 | 1 (2%) | 1 (2%) | 0 | 0.99 |